Valiant Laboratories Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Valiant Laboratories Ltd trades at ₹95.7, in a downtrend and 7 weeks into that stage. That is +33.4% against its own 200-day average. It sits at 100% of a 52-week range of ₹61 to ₹96. On relative strength it has no relative-strength read yet.

Today the stock is in a downtrend — week 7 of stage 4, confirmed. At ₹95.7 it trades +33.4% versus its 200-day average and sits at 100% of its 52-week range (₹61–₹96).

Against the market, two honest reads. Cumulative: over the last 1 months the stock moved +47% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Valiant Laboratories Ltd trades at 32.5× P/E, mid-range by its own standards (60th percentile). Its long-run median P/E is 25.1×, measured across 2.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 32.5× is mid-range by its own standards (60th percentile), against a long-run median of 25.1× measured over 2.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Valiant Laboratories Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Valiant Laboratories Ltd reported ₹115 Cr of revenue in the Jun 26 quarter, +144.7% year on year. That is the 6th straight quarter of year-on-year growth. Over 3 years it has compounded at −10.8% a year. The last full year, FY26, came in at ₹237 Cr. The last four reported quarters add to ₹305 Cr.

FY26 revenue came in at ₹237 Cr (+78.2% on the year), capping 3 years at −10.8% compound. The latest quarter (Jun 26) printed ₹115 Cr, +144.7% year on year — the 6th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +92.7% growth against the decade's −10.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +89.4% over the last 4 quarters against +42.1%/yr over the last 8 — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Valiant Laboratories Ltd's operating margin is 25.0% in the Jun 26 quarter, +20.0 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −4.6% to 11.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 25.0%, +20.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −4.6%–11.0%.

Why the margin moved: operating margin went +20.3 pp year on year while gross margin went +26.1 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Valiant Laboratories Ltd earned ₹21.0 Cr of net profit in the Jun 26 quarter, +950.0% year on year. It is the 2nd consecutive quarter of growth. The full FY26 year was a loss of ₹3.0 Cr. That is 18.3% of the quarter's revenue. The same quarter a year earlier earned ₹2.0 Cr.

Jun 26 profit was ₹21.0 Cr, +950.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹−3.0 Cr (null).

Why profit moved: revenue contributed +144.7% and the margin +20.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +200.0% vs revenue +92.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Valiant Laboratories Ltd's cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was ₹−10.0 Cr of operating cash against ₹−3.0 Cr of profit. After ₹35.0 Cr of capital spending, ₹−45.0 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY26: operating cash of ₹−10.0 Cr against reported profit of ₹−3.0 Cr, leaving free cash of ₹−45.0 Cr after ₹35.0 Cr of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Router verdict: the bigger cash user is investment — capital spending ran 19.4× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Valiant Laboratories Ltd's cash conversion cycle runs 54 days in FY26, up from 52 days in FY23. Capital spending ran ₹194 Cr over the last 3 years. At FY26 sales of ₹237 Cr each day of that cycle holds about ₹0.6 Cr, so roughly ₹35.0 Cr sits inside the business at any moment.

FY26: debtors at 144 days, inventory at 84 days — roughly 2.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 54 days, looser than FY23's 52.

The full loop: cash goes out to suppliers and production on day 0; stock waits 84 days to sell; customers pay about 144 days after that; and suppliers themselves are paid at 174 days — netting out to the 54-day cycle.

In money terms: at FY26 sales of ₹237 Cr, each day of the cycle holds about ₹0.6 Cr — so the 54-day loop keeps roughly ₹35.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹194 Cr over the last 3 fiscal years against ₹10.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹6.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Valiant Laboratories Ltd earns a ROCE of 1% in FY26. That is up from a trough of −2% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −1.3% net margin on 0.51× asset turns.

FY26 ROCE is 1%, recovered from a FY24 trough of −2% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): −1.3% net margin × 0.51× asset turns × 1.49× balance-sheet leverage ≈ −1.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Valiant Laboratories Ltd carries ₹46.0 Cr of borrowings against ₹311 Cr of equity in FY26, a debt-to-equity of 0.15. Operating profit covers the interest bill 3×. Over 3 years borrowings went from ₹60.0 Cr to ₹46.0 Cr. Capital spending ran ₹194 Cr across the last 3 of those years.

FY26: borrowings of ₹46.0 Cr against equity of ₹311 Cr — a debt-to-equity of 0.15. Operating profit covers the interest bill 3×. Over 3 years borrowings went from ₹60.0 Cr to ₹46.0 Cr while capital spending ran ₹194 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions cut 1.9 points of Valiant Laboratories Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 0.0% of the company. Promoters moved +0.0 points over the same window, to 74.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: −1.9 points over 8 quarters to 0.0%; Promoters: +0.0 points over 8 quarters to 74.9%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.

🚨 Why the register moved: foreign institutions drove it (−1.9 points) — distribution into the market’s bid.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Valiant Laboratories Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions